Trial Radar AI | ||
|---|---|---|
Clinical Trial NCT07419841 for Gastroesophageal Cancer (GC), Hepatocellular Carcinoma (HCC), Endometrial Cancer, Renal Cell Carcinoma (RCC) is not yet recruiting. See the Trial Radar Card View and AI discovery tools for all the details. Or ask anything here. | ||
A Phase 1 Study of the Safety and Tolerability of CTX-10726 Phase 1 70 First-in-Human Dose Escalation Open-Label
A Phase 1, Open-Label, Multiple-Ascending Dose Study of the Safety and Tolerability of CTX-10726 in Patients With Advanced Malignancies
- CTX-10726-001
| Participant Group/Arm | Intervention/Treatment |
|---|---|
ExperimentalDose Escalation Cohort 1 Escalating doses of CTX-10726 | CTX-10726 Intravenous (IV) infusion (0.3-10.0mg/kg) every two weeks. |
ExperimentalDose Expansion Cohort 2 Dose of CTX-10726 depending on Cohort 1 data | CTX-10726 Intravenous (IV) infusion (0.3-10.0mg/kg) every two weeks. |
| Outcome Measure | Measure Description | Time Frame |
|---|---|---|
Cohort 1: Evaluate the safety and tolerability of CTX-10726 by incidence of treatment-emergent adverse events (TEAEs) in escalating doses | Incidence of dose limiting toxicities (DLTs), treatment-emergent adverse events (TEAEs), and/or changes in clinical laboratory abnormalities. | From first dose of CTX-10726 (Cycle 1 Day 1, Cycle = 2 weeks) until 30 days after the last dose of CTX-10726, average of 6 months) |
Cohort 1: Determine the dose(s) of CTX-10726 to be further examined in Cohort 2 and Phase 2 studies | From first dose of CTX-10726 (Cycle 1 Day 1, Cycle = 2 weeks ) until 30 days after the last dose of CTX-10726 (average of 6 months) | |
Cohort 2: Evaluate the safety and tolerability of CTX-10726 by incidence of treatment-emergent adverse events (TEAEs) at dose(s) selected from Cohort 1 | Incidence of treatment-emergent adverse events (TEAEs) | From first dose of CTX-10726 (Cycle 1 Day 1, Cycle = 2 weeks) until 30 days after the last dose of CTX-10726 (up to 2 years) |
| Outcome Measure | Measure Description | Time Frame |
|---|---|---|
Objective Response Rate (ORR) (Percentage of Participants With Objective Response) as per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 | Baseline until confirmed disease progression (up to 2 years) | |
Duration of Response (DOR) as per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 | From the date of first confirmed complete response (CR) or partial response (PR) until the first date of recurrent or progressive disease (up to 2 years) | |
Disease Control Rate (DCR) percentage of patients with best overall response of CR, PR, or SD as per RECIST version 1.1 | From first dose of CTX-10726(Cycle 1 Day 1,Cycle = 2 weeks ) until disease progression or death, whichever occur first (up to 2 years) | |
Clinical Benefit Rate (CBR) percentage of patients with best overall response of CR, PR, or SD for ≥ 6 months as per RECIST version 1.1 | From first dose of CTX-10726(Cycle 1 Day 1,Cycle = 2 weeks ) until disease progression or death, whichever occur first (up to 2 years) | |
Progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 | From first dose of CTX-10726(Cycle 1 Day 1,Cycle = 2 weeks ) until disease progression or death, whichever occur first (up to 2 years) | |
Overall Survival (OS) | From first dose of CTX-10726 (Cycle 1 Day 1,Cycle = 2 weeks) until death (up to 2 years) | |
Maximum serum concentration (Cmax) of CTX-10726 | From first dose of CTX-10726 (Cycle 1 Day 1 = 2 weeks) until treatment discontinuation | |
Time of maximum serum concentration (Tmax) of CTX-10726 | From first dose of CTX-10726 (Cycle 1 Day 1, Cycle = 2 weeks) until treatment discontinuation | |
Trough concentration (Ctrough) of CTX-10726 | From first dose of CTX-10726 (Cycle 1 Day 1, Cycle = 2 weeks) until treatment discontinuation | |
Area under the curve (AUC) of CTX-10726 | From first dose of CTX-10726 (Cycle 1 Day 1,Cycle = 2 weeks) until treatment discontinuation | |
Clearance (CL) of serum concentrations of CTX-10726 | From first dose of CTX-10726 (Cycle 1 Day 1, Cycle = 2 weeks) until treatment discontinuation | |
Volume of distribution (Vd) of serum concentrations of CTX-10726 | From first dose of CTX-10726 (Cycle 1 Day 1, Cycle = 2 weeks) until treatment discontinuation | |
Terminal elimination half-life (t1/2) of serum concentrations of CTX-10726 | From first dose of CTX-10726 (Cycle 1 Day 1, Cycle = 2 weeks) until treatment discontinuation | |
Dose response for CTX-10726 | From first dose of CTX-10726 (Cycle 1 Day 1, Cycle = 2 weeks) until treatment discontinuation | |
Assess the immunogenicity of CTX-10726 screen for the presence and development of antibodies against CTX-10726 | From first dose of CTX-10726 (Cycle 1 Day 1, Cycle = 2 weeks) until end of treatment visit |
- Age 18 years or older.
- Patients must have a histologically or cytologically confirmed diagnosis of locally advanced unresectable or metastatic disease that is relapsed/refractory to standard therapy or for which no effective standard therapy is available, including:
2a: Renal Cell Carcinoma (RCC)
Histologically confirmed diagnosis of renal cell carcinoma (with clear cell component) with advanced or metastatic disease that is not amenable to cure by surgery or other means.
Patients who have progressed after a minimum of 2 doses of a programmed cell death 1 (PD-1)/ programmed cell death ligand 1 (PDL1) treatment.
Patients must have received at least one regimen including a tyrosine kinase inhibitor (TKI).
Patients who received immunomodulatory drugs (thymosin, interferon, interleukin, etc.) within 2 weeks before the first dose or received major surgical treatment within 3 weeks before the first dose are not eligible.
2b: Hepatocellular Carcinoma (HCC)
Patients who have progressed after a minimum of 2 doses of a PD-1/PDL1 treatment.
Patient must have received one of the following regimens: ipilimumab+nivolumab, tremelimumab+durvalumab or atezolizumab+bevacizumab.
Hepatic function: Child -Pugh A and Child-Pugh B7.
Receipt of local area treatment of the liver more than 4 weeks prior to the first dose is allowed.
2c. Gastroesophageal Cancer (GC)
Patients who have progressed after a minimum of 2 doses of a PD-1/PDL1 treatment.
Patients must have received prior treatment with platinum-based chemotherapy.
2d: Endometrial Cancer (EC)
Patients must have received at least 1 cycle of platinum-based chemotherapy.
Patients with newly diagnosed advanced endometrial cancer that have persistent lesion(s) after standard treatment with surgery and chemotherapy ± radiotherapy.
Patients with MSI- high or deficient DNA mismatch repair (dMMR) tumors who have progressed after a minimum of 2 doses of a PD-1/PDL1 treatment.
3. Patients must have measurable disease per RECIST 1.1. Tumor sites that are considered measurable must not have received prior radiation.
4. Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
5. Adequate organ function including:
Bone marrow function defined by absolute neutrophil (ANC) of ≥ 1.5×109/L, platelet count of ≥ 100.0×109/L, and hemoglobin of ≥ 9.0 g/dL (with or without transfusion).
Hepatic function defined as serum total bilirubin ≤ 1.5 × ULN, AST/ALT ≤ 2.5 × ULN (or ≤ 5 × ULN in patients with liver metastases).
Renal function defined as creatinine clearance ≥ 30 mL/min by Cockcroft Gault equation.
Cardiac function with Left Ventricular Ejection Fraction (LVEF) ≥ 50%.
6. Female patients must be surgically sterile (or have a monogamous partner who is surgically sterile) or be at least 2 years postmenopausal or commits to use 2 acceptable forms of birth control (defined as the use of an intrauterine device, a barrier method with spermicide, condoms, any form of hormonal contraceptives) or abstinence for the duration of the study and for 4 months following the last dose of study treatment. Male patients must be sterile (biologically or surgically) or commit to the use of a reliable method of birth control (condoms with spermicide) for the duration of the study and for 4 months following the last dose of study treatment.
7. Female patients who are women of childbearing potential (WOCBP) must have a negative serum pregnancy test at Screening within 7 days of dosing with CTX-10726.
8. Prior anticancer therapy > 28 days (or 2 half-lives for proteins, whichever is longer), radiotherapy > 7 days (concurrent localized palliative radiotherapy is allowed during CTX-10726 treatment), therapeutic surgical intervention > 21 days, blood transfusion > 14 days, or biopsy or minor surgery (excluding placement of vascular access devices) > 7 days prior to the first dose of CTX-10726.
9. Resolution of all prior anti-cancer therapy toxicities ≤ Grade 2.
10. Capable of understanding and complying with protocol requirements
11. Signed and dated institutional review board (IRB) approved informed consent form (ICF) before any protocol-directed screening procedures are performed.
Developed clinically significant adverse reaction to PD-1 or PD-L1 therapy, including immune related adverse reactions, which led to discontinuation of treatment.
Prior organ transplantation.
History of arterial or venous thrombosis or stroke or transient ischemic attack within 6 months prior to the first dose.
History of other neoplasms within 3 years prior to screening, except basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or cervical cancer in situ that has undergone successful surgery.
Known, symptomatic central nervous system (CNS) and brain metastasis.
A pleural, abdominal or pericardial effusion that is clinically symptomatic or requires repeated management (puncture or drainage, etc).
Imaging at screening that shows the tumor surrounds important blood vessels or had obvious necrosis and voids, and the investigators deems that it might cause bleeding risk.
The presence of severe, unhealed or open wounds, active ulcers, or untreated fractures at the time of screening.
A history of significant bleeding tendency or severe coagulopathy.
Current therapeutic dose of anticoagulant or thrombolytic medication within 14 days of the first dose. Note: prophylactic use of low molecular heparin is allowed.
Current or recent use of aspirin (> 325 mg/day) or other non-steroidal anti-inflammatory drugs (NSAIDs) within 14 days of first dose.
Uncontrolled diabetes mellitus (HbA1c >8%) on standard therapy.
The presence of poorly controlled hypertension (systolic blood pressure \[SBP\]/diastolic blood pressure \[DBP\]) >140/90 mmHg (eg, patient with SBP/DBP > 140/90 mmHg despite the best care including optimizing the anti-hypertensive medication regimen.
Pregnant or lactating WOCBP.
Patients with evidence of active hepatitis B virus (HBV), hepatitis C virus (HCV) or human immunodeficiency virus (HIV) infection. Patients with positive HBsAg and/or detectable HBV DNA are eligible only if adequately controlled on antiviral therapy according to institutional standards and liver function eligibility criteria are also met. HCV patients showing sustained viral response or patients with immunity to HBV infection may enroll.
- Hepatitis B subjects who meet the following criteria are also eligible for inclusion: HBV viral load must be < 1000 copies /ml (200 IU/ml) prior to initial dosing, and subjects should receive anti-HBV therapy to avoid viral reactivation throughout the duration of study chemotherapy drug treatment. For subjects with anti-HBC (+), HBsAg (-), anti-HBS (-), and HBV viral load (-), prophylactic anti-HBV therapy is not required, but close monitoring of viral reactivation is required.
- HIV-infected subjects who meet the following criteria are eligible for inclusion: HIV-RNA levels below the lower limit of detection.
Active HCV-infected subjects (HCV antibody positive and HCV-RNA levels above the lower limit of detection).
Patients that received attenuated vaccination within 4 weeks prior to screening or planning to receive attenuated vaccination during the study period.
Current or recent systemic therapy with immunosuppressive agents within 7 days before the start of CTX-10726 treatment. Topical, intranasal, intraocular, or inhaled corticosteroids and physiologic replacement for patients with adrenal insufficiency are allowed.
Active autoimmune disease or medical conditions requiring chronic steroid (i.e., > 10 mg/day prednisone or equivalent) or immunosuppressive therapy. Patients with a prior history of autoimmune disease may be eligible following discussion with the Medical Monitor.
Active or prior documented idiopathic pulmonary fibrosis or idiopathic pneumonia; current acute lung disease, interstitial lung disease or pneumonia (except localized interstitial pneumonia due to radiotherapy induction), pulmonary fibrosis, severe respiratory distress, pulmonary insufficiency or continuous oxygenation.
Other medical conditions in the opinion of the Investigator and/or Sponsor Medical Monitor may interfere with the conduct and/or interpretation of the current study, including: a. Congestive heart failure (> New York Heart Association Class II), active coronary artery disease, unevaluated new onset angina within 3 months or unstable angina (angina symptoms at rest) or clinically significant cardiac arrhythmias. b. QTc interval (using Fridericia correction calculation) > 480 msec.
Compass TherapeuticsNew York